verekitug
verekitug: developed by 1 company · 4 clinical trials tracked.
verekitug evidence translation
What we can confirm
4 tracked trials
What it means
What to watch
Prepared research question
How could verekitug → UPB affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Upstream Bio, Inc. (UPB) Severe Asthma; Chronic Obstructive Pulmonary Disease; Chroni… | Phase 2 |
Clinical Trials (4)
A Phase 2b Randomized, Double-blind, Placebo-controlled, Parallel-Group Study to Assess Efficacy and Safety of Verekitug (UPB-101) in Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
Primary endpoint: Annualized rate of moderate or severe COPD exacerbation events
A Long-Term Extension Study to Evaluate Safety and Efficacy of Verekitug (UPB-101) in Adult Participants With Severe Asthma Who Completed the VALIANT Trial
Primary endpoint: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center, Dose-ranging Study to Evaluate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)
Primary endpoint: Annual Asthma Exacerbation Rate (AAER)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal Polyps on a Background of Nasal Corticosteroids (VIBRANT)
Primary endpoint: Change From Baseline in Nasal Polyp Score (NPS) at Week 24
Frequently asked questions
Who is developing verekitug?
verekitug is being developed by Upstream Bio, Inc..
How many clinical trials involve verekitug?
BioSniper tracks 4 clinical trials involving verekitug.